Asthma treatment goals currently focus on symptom and exacerbation control rather than
remission. Remission is not identical to cure, but is a step closer. This review considers the …

Severe asthma affects about 10% of the population with asthma and is characterized by low
lung function and a high count of blood leukocytes, mainly eosinophils. Various definitions …

Drug nanodelivery systems (DNDSs) are fascinated cargos to achieve outstanding
therapeutic results of various drugs or natural bioactive compounds owing to their unique …

Fucoxanthin is isolated from brown algae and was previously reported to have multiple
pharmacological effects, including anti-tumor and anti-obesity effects in mice. Fucoxanthin …

Background Remission is proposed as a multicomponent outcome for patients with severe
asthma. Objective This post hoc analysis of QUEST (NCT02414854) and TRAVERSE …

Introduction In recent years, monoclonal antibodies targeting Type-2 inflammatory pathways
have been developed for severe asthma treatment. However, even when patients are …

In the field of severe asthma, the concept of disease control has recently been integrated by
the one of clinical remission. With this new concept, we move on to analyze the efficacy of …

In the present review, we focused on recent translational and clinical discoveries in asthma
immunology, facilitating phenotyping and stratified or personalized interventions for patients …

Asthma is a chronic respiratory disease marked by heterogeneity and variable clinical
outcomes. Recent therapeutic advances have highlighted patients achieving optimal …

Background Numerous investigations have previously evaluated the association of
interleukin (IL) 4 gene polymorphisms and the risk of asthma, conferring inconsistent results …